728-P: Metabolomic Profiling of Obese Patients Treated with Liraglutide Suggests Its Role in Modulating Inflammation

Le résumé fourni par la source

Introduction and Objective: Liraglutide, a derivative of the human incretin glucagon-like peptide-1 (GLP-1), is approved for the treatment of both type 2 diabetes (T2D) and obesity. This study aimed to explore the metabolic benefits of Liraglutide in patients with obesity or overweight, focusing on changes in vital signs, anthropometric measures (such as weight, body mass index, and body composition), biochemical markers, and blood-based metabolomic profiles. Methods: A total of 49 subjects with a BMI greater than 30 kg/m² and no history of T2D were enrolled in the study. Participants were administered a once-daily subcutaneous dose of 3.0 mg liraglutide, along with a reduced calorie diet tailored to their individual estimated basal metabolic rate. Plasma samples were collected at baseline, 12 weeks, and 24 weeks. The primary outcome was the change in body weight, while secondary outcomes included alterations in anthropometric measurements, pro-inflammatory cytokines (IL-1β, IL-6, IL-8, and TNF-α), and plasma metabolome, analysed using Mass Spectrometry (MS). Results: At week 24, participants were categorised based on their weight loss (WL) response: poor responders (<5% WL, n=22), good responders (5-10% WL, n=18), and super-responders (>10% WL, n=9). Compared to non-responders, super-responders showed significant downregulation of phosphatidylcholine and triglycerides (p<0.001), and upregulation of sphingosine 1 phosphate (S1P) (p<0.005). A significant positive correlation was found between IL-6 levels and weight loss (r=0.732, p<0.001). In all super-responders, IL-6 levels were notably decreased, while S1P expression was significantly elevated. Conclusion: In this study, liraglutide administration produced several notable effects in individuals who responded exceptionally well to the treatment. Specifically, it reduced inflammation, as evidenced by an increase in S1P expression, known to have anti-inflammatory properties, and a decrease in IL-6 levels in the super-responders. Disclosure A. Murphy: None. L. Spencer: None. A. Duggirala: None. H.S. Randeva: Advisory Panel; Novo Nordisk. P.G. McTernan: None. G. Tripathi: None.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.